Recursion Pharmaceuticals, Inc. RXRX Accrued early discovery expenses
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept rxrx:AccruedEarlyDiscoveryExpensesCurrent.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s accrued early discovery expenses.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s accrued early discovery expenses?
- Recursion Pharmaceuticals, Inc. (RXRX) reported accrued early discovery expenses of $7.54M in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s accrued early discovery expenses changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s accrued early discovery expenses increased by 29.3% year-over-year, from $5.83M to $7.54M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s accrued early discovery expenses?
- Over 5 years (2020 to 2025), Recursion Pharmaceuticals, Inc.'s accrued early discovery expenses has grown at a 68.4% compound annual growth rate (CAGR), from $338K to $4.58M.